Danish pharmaceutical company Novo Nordisk (NYSE: NVO) is pioneering a new wave of medical treatment for diabetes and obesity ...
Critics, including Senator Bernie Sanders, question whether the push to block alternatives is truly about safety — or simply ...
The full-year cost of care for U.S. patients with obesity, two years after starting on Novo Nordisk's Wegovy or similar GLP-1 ...
The University of California, Davis today announced an expanded collaboration with the BioInnovation Institute (BII) to ...
Economic data in Q3 indicated lower inflation and employment, prompting the Fed to cut interest rates by 50bps, influencing ...
10h
The active ingredient in Ozempic and Wegovy has once again proven to have health effects outside of weight loss in a huge ...
The pharmaceutical company’s stock is relatively cheap, representing an opportunity for patient value investors.
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback